PRAXIS PRECISION MEDICINES I (PRAX) Stock Price, Quote, News and Overview
NASDAQ:PRAX - Nasdaq - US74006W2070 - Common Stock - Currency: USD
PRAX Quote, Performance and Key Statistics
37.55
-0.76 (-1.98%)
The current stock price of PRAX is 37.55 USD. In the past month the price increased by 4.31%. In the past year, price decreased by -14.81%.
PRAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.06B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About PRAX
Company Profile
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The company is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
Company Info
PRAXIS PRECISION MEDICINES I
99 High Street, 30th Floor
Boston MASSACHUSETTS 02142 US
CEO: Marcio Souza
Employees: 82
Phone: 16173008460
PRAXIS PRECISION MEDICINES I / PRAX FAQ
What is the stock price of PRAXIS PRECISION MEDICINES I today?
The current stock price of PRAX is 37.55 USD. The price decreased by -1.98% in the last trading session.
What is the ticker symbol for PRAXIS PRECISION MEDICINES I stock?
The exchange symbol of PRAXIS PRECISION MEDICINES I is PRAX and it is listed on the Nasdaq exchange.
On which exchange is PRAX stock listed?
PRAX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRAXIS PRECISION MEDICINES I stock?
17 analysts have analysed PRAX and the average price target is 101.26 USD. This implies a price increase of 169.66% is expected in the next year compared to the current price of 37.55. Check the PRAXIS PRECISION MEDICINES I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRAXIS PRECISION MEDICINES I worth?
PRAXIS PRECISION MEDICINES I (PRAX) has a market capitalization of 757.01M USD. This makes PRAX a Small Cap stock.
How many employees does PRAXIS PRECISION MEDICINES I have?
PRAXIS PRECISION MEDICINES I (PRAX) currently has 82 employees.
What are the support and resistance levels for PRAXIS PRECISION MEDICINES I (PRAX) stock?
PRAXIS PRECISION MEDICINES I (PRAX) has a support level at 37.34 and a resistance level at 40.25. Check the full technical report for a detailed analysis of PRAX support and resistance levels.
Is PRAXIS PRECISION MEDICINES I (PRAX) expected to grow?
The Revenue of PRAXIS PRECISION MEDICINES I (PRAX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PRAX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRAXIS PRECISION MEDICINES I (PRAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRAX, evaluating the profitability, health, valuation and growth aspects
- PRAXIS PRECISION MEDICINES I (PRAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRAXIS PRECISION MEDICINES I (PRAX) Sales and EPS estimates to see what analysts future expectations are.
- PRAXIS PRECISION MEDICINES I (PRAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRAXIS PRECISION MEDICINES I (PRAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRAXIS PRECISION MEDICINES I (PRAX) Stock Chart to make your own analysis
- PRAXIS PRECISION MEDICINES I (PRAX) Latest news and press-releases to stay up to date.
Does PRAXIS PRECISION MEDICINES I (PRAX) stock pay dividends?
PRAX does not pay a dividend.
When does PRAXIS PRECISION MEDICINES I (PRAX) report earnings?
PRAXIS PRECISION MEDICINES I (PRAX) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of PRAXIS PRECISION MEDICINES I (PRAX)?
PRAXIS PRECISION MEDICINES I (PRAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.72).
What is the Short Interest ratio of PRAXIS PRECISION MEDICINES I (PRAX) stock?
The outstanding short interest for PRAXIS PRECISION MEDICINES I (PRAX) is 9.47% of its float. Check the ownership tab for more information on the PRAX short interest.
PRAX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PRAX. When comparing the yearly performance of all stocks, PRAX is a bad performer in the overall market: 87.38% of all stocks are doing better.
PRAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRAX. PRAX has a great financial health rating, but its profitability evaluates not so good.
PRAX Financial Highlights
Over the last trailing twelve months PRAX reported a non-GAAP Earnings per Share(EPS) of -10.72. The EPS increased by 32.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.4% | ||
| ROE | -48.4% | ||
| Debt/Equity | 0 |
PRAX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to PRAX. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -27.73% and a revenue growth -100% for PRAX